Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Ismaeel Hashemi, University of Michigan Health System.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Ismaeel Hashemi, University of Michigan Health System Identifier:
First received: August 27, 2012
Last updated: August 29, 2012
Last verified: August 2012
The investigators hypothesize that using Cyproheptadine in a placebo-controlled crossover trial would help relieve abdominal pain associated with FAP in children, achieving a greater response than that observed with placebo. In addition to assessing self-report of pain and other symptoms, the investigators also propose to perform experimental somatic pain testing to determine if there is evidence of peripherally-maintained central sensitization in children with FAP. The investigators also hypothesize that there will be an increase in somatic pain threshold after completion of a Cyproheptadine course compared to baseline testing prior to treatment, and compared to placebo. This would allow children with FAP to return to normal function, improve symptoms and overall general well-being

Condition Intervention Phase
Functional Abdominal Pain
Drug: Cyproheptadine
Drug: sugar pill
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

Resource links provided by NLM:

Further study details as provided by Ismaeel Hashemi, University of Michigan Health System:

Primary Outcome Measures:
  • Pressure Pain Threshold [ Time Frame: 10 weeks ]
    This will be a randomized blinded placebo controlled cross-over study. Forty children aged 8 to 18 years diagnosed with FAP using the Rome III criteria will be recruited. Pressure Pain testing will be performed before and after crossover between drug and placebo to evaluate for objective differences in pressure pain thresholds

Secondary Outcome Measures:
  • Improvement in abdominal pain [ Time Frame: 10 weeks ]
    Evaluated using surveys.

Estimated Enrollment: 40
Study Start Date: August 2012
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cyproheptadine
4 weeks of cyproheptadine or placebo with crossover to the other
Drug: Cyproheptadine
4 weeks of cyproheptadine or placebo with crossover to the other
Other Name: Periactin
Experimental: Sugar Pill
4 weeks of cyproheptadine or placebo with crossover to the other
Drug: sugar pill
4 weeks of cyproheptadine or placebo with crossover to the other
Other Name: placebo


Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 8 and 18 years-old
  • Diagnosed with Functional Abdominal Pain using the Rome III Criteria must include all* of the following:

    1. Episodic or continuous abdominal pain
    2. Insufficient criteria for other FGIDs
    3. No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject's symptoms

      • Criteria fulfilled at least once per week for at least 2 months prior to diagnosis
  • Written informed consent obtained from the patient/guardian before the initiation of any study-specific procedures

Exclusion Criteria:

  • Age < 8 years-old or Age >18 years-old
  • Child or parent are non-English speakers
  • Child is using other CNS depressants (cyproheptadine causes drowsiness, and may enhance the adverse/toxic effect of other CNS Depressants e.g. opioids, barbiturates, Droperidol, Hydroxyzine, Alcohol)(29)
  • Child has a history of hypersensitivity to Cyproheptadine products
  • Child is currently using monoamine oxidase inhibitor (MAOI e.g. Nardil, Marplan, Parnate) (can cause a prolonged or intensified anticholinergic effect)
  • Child was treated with Cyproheptadine in the past 4 weeks
  • Child is currently using anticholinergic (can cause an additive anticholinergic effect e.g. Pramlintide)
  • Concomitant SSRI use ( being a serotonin antagonist, may oppose effects)
  • Concomitant use of Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine
  • Concomitant use of Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central) and vice versa.
  • Child has a personal history of glaucoma
  • Child has asthma (can cause thickening of bronchial secretions) (27,28)
  • History of liver dysfunction/disease (can cause hepatitis)
  • History of cardiac disease (not specific to Cyproheptadine, antihistamines have been associated with hypotension, palpitations, tachycardia and arrhythmias) (28,29).
  • Females who are known to be pregnant will also be excluded. All females who are of child bearing age, or are already menstruating will perform a urine pregnancy test before enrolling.
  • Any children who have difficulties swallowing tablets will receive teaching on how to swallow tablets. If they are still unable to do so, they will not participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01675050

Contact: Emilia Mondragon

United States, Michigan
UmichiganHS Recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Emilia Mondragon   
Principal Investigator: Ismaeel Hashemi, MD         
Sponsors and Collaborators
University of Michigan
  More Information

Responsible Party: Ismaeel Hashemi, Fellow Physician, University of Michigan Health System Identifier: NCT01675050     History of Changes
Other Study ID Numbers: HUM00056045
Study First Received: August 27, 2012
Last Updated: August 29, 2012

Additional relevant MeSH terms:
Abdominal Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Dermatologic Agents
Gastrointestinal Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Serotonin Antagonists
Serotonin Agents
Anti-Allergic Agents processed this record on May 25, 2017